2016
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527
Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A. Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. Journal Of Clinical Oncology 2016, 35: 421-431. PMID: 27992272, PMCID: PMC5455700, DOI: 10.1200/jco.2016.69.4182.Peer-Reviewed Original ResearchConceptsOlder patientsMetastatic trialsAdjuvant trialsBreast cancerHormone receptor-negative tumorsBreast cancer treatment trialConclusion Older patientsSystemic therapy trialsReceptor-negative tumorsBreast cancer trialsCancer treatment trialsYears of ageAccrual challengesNeoadjuvant trialsAdjuvant studiesPatient ageTherapy cessationLymph nodesTherapeutic trialsTreatment cessationTumor sizeDisease characteristicsPatient populationTreatment trialsCancer trials
2014
Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study
Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study. Journal Of Clinical Oncology 2014, 32: 927-934. PMID: 24516021, PMCID: PMC3948095, DOI: 10.1200/jco.2013.51.1261.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerCardiac eventsOlder patientsBreast cancerTrastuzumab completionAdjuvant trastuzumabTreatment completionOlder womenHuman epidermal growth factor receptorAdjuvant trastuzumab useAge 76 yearsDays of therapyMost older patientsSignificant cardiac eventsMultivariable logistic regressionEpidermal growth factor receptorGrowth factor receptorMore comorbiditiesTrastuzumab useComorbidity scorePatient ageHospital admissionOptimal treatmentLower oddsMedicare data
2011
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer
Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Research And Treatment 2011, 131: 1061-1066. PMID: 22080245, DOI: 10.1007/s10549-011-1872-9.Peer-Reviewed Original ResearchConceptsBasal-like carcinomasBreast cancerPathologic featuresYoung womenPatient ageTumor stageMolecular phenotypesInvasive breast cancerLuminal B tumorsPoor prognostic featuresDifferent age groupsClinical characteristicsB tumorsReceptor statusPrognostic featuresCentral reviewMedical recordsTumor gradeHigh prevalenceLarge cohortGeneral populationAge groupsBiomarker expressionCancerHER2Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates?
Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates? The Breast Journal 2011, 18: 23-27. PMID: 22017599, DOI: 10.1111/j.1524-4741.2011.01178.x.Peer-Reviewed Original ResearchConceptsPositive sentinel lymph nodesSentinel lymph node biopsySentinel lymph nodesAxillary node dissectionCompletion axillary node dissectionLow-risk patient populationAdjuvant treatment patternMedian patient agePercent of patientsLymph node biopsyStandard of careNodal radiationNode dissectionMicrometastatic diseaseNode biopsyLymph nodesPatient ageTreatment patternsPatient populationBreast cancerClinical dataRadiation therapyPatientsDiseaseMacrometastasis
2010
Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians
Mandelblatt JS, Sheppard VB, Hurria A, Kimmick G, Isaacs C, Taylor KL, Kornblith AB, Noone AM, Luta G, Tallarico M, Barry WT, Hunegs L, Zon R, Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H. Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians. Journal Of Clinical Oncology 2010, 28: 3146-3153. PMID: 20516438, PMCID: PMC2903313, DOI: 10.1200/jco.2009.24.3295.Peer-Reviewed Original ResearchConceptsChemotherapy usePatient preferencesChemotherapy decisionsOlder womenCooperative group sitesAdjuvant chemotherapy decisionsNonmetastatic breast cancerHigher patient ratingsTimes higher oddsPatient ageChemotherapy ratesPatient interviewsProvider communicationPatient ratingsBreast cancerPhysician surveyHigher oddsChemotherapyLogistic regressionWomenLimited dataWomen's preferencesImportant correlatesGroupComorbidities
2009
Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age.
Lichtman S, Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H. Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age. Cancer Research 2009, 69: 6112. DOI: 10.1158/0008-5472.sabcs-6112.Peer-Reviewed Original ResearchFirst-line therapyLines of therapyBreast cancerPatient ageOlder womenSide effectsLine therapyOlder adultsIncidence of gradeOnset of gradePrior chemotherapy regimenSecond-line patientsSingle-agent paclitaxelDoses of paclitaxelMetastatic breast cancerOnset of neurotoxicityRisk of fallsStandard prognostic variablesAge categoriesLikelihood of responseBetter performance scoresPerformance scoresBilirubin elevationPaclitaxel efficacyWeekly paclitaxel
2006
Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer
Naughton M, Gu L, Wang X, Seidman A, Winer E, Kornblith A. Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer. Journal Of Clinical Oncology 2006, 24: 674-674. DOI: 10.1200/jco.2006.24.18_suppl.674.Peer-Reviewed Original ResearchNegative patientsQOL differencesGreater efficacyMain trial resultsPrior radiation therapyMetastatic breast cancerPhase III studyTreatment of patientsMain outcome measuresEORTC-C30Prior chemotherapyBreast symptomsIII studyPerformance statusPatient ageHour infusionTreatment armsBreast moduleGlobal QoLCancer symptomsBreast cancerClinical dataQoL dataOutcome measuresRadiation therapy